Biocius Life Sciences and Agilent Technologies have launched the RF360 high-resolution system for high-throughput screening of in vitro ADME assays in drug discovery applications.
The RF360 high-resolution system will be on display in the Biocius hospitality suite at the 58th Annual American Society for Mass Spectrometry Conference in Salt Lake City, Utah, from 23-27 May 2010.
The instrument is said to combine the accurate mass capabilities of Agilent's time-of-flight (ToF) mass spectrometers and the sample processing speed of Rapidfire technology.
The companies claim that the instrument revolutionises in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.
This approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods, while requiring a minimal amount of operator input.
Rapidfire technology combined with ToF mass spectrometers enables a range of ADME assays, including drug-drug interaction, metabolic stability, Caco, PAMPA and others.
When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan ToF-MS mode.
Post-acquisition, the relevant data is extracted using Rapidfire software, eliminating the time-consuming and labour-intensive steps of LC/MS method development and batch analysis.